Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and
pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant
docetaxel therapy.
PURPOSE: To evaluate whether dose-dense scheduling with (peg)filgrastim support may improve
the clinical and pathologic complete response rate (pCR) and safety profile of single agent
neoadjuvant docetaxel therapy. To determine the changes in molecular markers that occurs with
single agent docetaxel, tissue will be obtained at the end of the four cycles of docetaxel
(either by repeat biopsy or definitive surgery).